《半新股》雍禾醫療(02279.HK)獲部分行使超額配股權 惟股價急挫19%尋底
雍禾醫療(02279.HK)獲部分行使超額配股權,但該股終止連續三天反覆平收於15.8元的勢頭,今早急跌曾低見12.64元創上市新低,現報12.78元,急挫19%,成交177萬股,涉資近2,415萬元。
雍禾是內地領先的專門從事提供一站式毛髮醫療服務的醫療集團。股份於12月13日以每股15.8元在港上市。雍禾昨晚公布,聯席全球協調人以每股15.8元部份行使超額配股權,涉及合共712.45萬股(佔發售總數7.5%),額外集資淨額1.08億元。此外,有關全球發售穩定價格期已於5日結束。期間,穩定價格操作人在市場上購入合共946.8萬股,每股作價介乎15.16至15.8元;及出售合共242.9萬股,每股作價介乎17.6至19元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.